Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

After hours: March 21 at 7:56:15 PM EDT Loading Chart for BOX ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Transcranial Magnetic Stimulation (TMS), and Spravato®. This acquisition, which is still subject to financial audits and definitive agreements, is expected to enhance HOPE's revenue projections ...

President Trump's unpredictable policies, especially the global tariff war, have led to significant market volatility and economic concerns, with the Nasdaq 100 down 14%. Defensive stocks, bonds ...